188 related articles for article (PubMed ID: 29394852)
1. [A Case Report of Curative Surgery for Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination after Gemcitabine Chemotherapy].
Ichikawa Y; Yamada D; Eguchi H; Iwagami Y; Noda T; Asaoka T; Wada H; Kawamoto K; Gotoh K; Kobayashi S; Tatsumi M; Takeyari M; Mori M; Doki Y
Gan To Kagaku Ryoho; 2017 Nov; 44(12):2014-2016. PubMed ID: 29394852
[TBL] [Abstract][Full Text] [Related]
2. A case of metachronous oligo-hepatic and peritoneal metastases of pancreatic cancer with a favorable outcome after conversion surgery combined with perioperative sequential chemotherapy.
Tohyama T; Tanno Y; Murakami T; Hayashi T; Fujimoto Y; Takehara K; Seshimo K; Fukuhara R; Omori M; Matsumoto T
Clin J Gastroenterol; 2024 Apr; 17(2):371-381. PubMed ID: 38291249
[TBL] [Abstract][Full Text] [Related]
3. The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients with unresectable pancreatic ductal adenocarcinoma.
Kato A; Naiki-Ito A; Naitoh I; Hayashi K; Nakazawa T; Shimizu S; Nishi Y; Okumura F; Inoue T; Takada H; Kondo H; Yoshida M; Takahashi S; Joh T
Hum Pathol; 2018 Apr; 74():92-98. PubMed ID: 29339176
[TBL] [Abstract][Full Text] [Related]
4. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M
Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study).
Yamamoto T; Fujii T; Hirano S; Motoi F; Honda G; Uemura K; Kitayama J; Unno M; Kodera Y; Yamaue H; Shimokawa T; Hashimoto D; Yamaki S; Yoshitomi H; Miura F; Ueno H; Sekimoto M; Satoi S;
Trials; 2022 Feb; 23(1):119. PubMed ID: 35123553
[TBL] [Abstract][Full Text] [Related]
7. Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
Yanagimoto H; Satoi S; Yamamoto T; Hirooka S; Yamaki S; Kotsuka M; Ryota H; Michiura T; Inoue K; Matsui Y; Tsuta K; Kon M
Nutr Cancer; 2016; 68(2):234-40. PubMed ID: 26847832
[TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis.
Kaneko T; Sugimori K; Tozuka Y; Fukushima T; Okada K; Oka H; Okazaki H; Maeda S
Clin J Gastroenterol; 2019 Oct; 12(5):484-489. PubMed ID: 30993653
[TBL] [Abstract][Full Text] [Related]
9. [A case of liver metastasis of pancreatic duct carcinoma successfully treated with gemcitabine].
Tsujie M; Nakamori S; Nakazuru S; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Gan To Kagaku Ryoho; 2003 Feb; 30(2):297-301. PubMed ID: 12610883
[TBL] [Abstract][Full Text] [Related]
10. [Modern possibilities of chemotherapy in patients with ductal pancreatic adenocarcinoma].
Kopchak VM; Kopchak KV; Romaniv IaV
Klin Khir; 2006 Feb; (2):23-5. PubMed ID: 16826811
[TBL] [Abstract][Full Text] [Related]
11. Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?
Liang C; Shi S; Meng Q; Liang D; Ji S; Zhang B; Qin Y; Xu J; Ni Q; Yu X
Cell Mol Life Sci; 2018 Mar; 75(6):1001-1012. PubMed ID: 28993833
[TBL] [Abstract][Full Text] [Related]
12. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.
Van Laethem JL; Demols A; Gay F; Closon MT; Collette M; Polus M; Houbiers G; Gastelblum P; Gelin M; Houtte PV; Closset J
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):974-80. PubMed ID: 12829132
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis.
Takahara N; Nakai Y; Ishigami H; Saito K; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Yamashita H; Isayama H; Seto Y; Koike K
Invest New Drugs; 2021 Feb; 39(1):175-181. PubMed ID: 32772340
[TBL] [Abstract][Full Text] [Related]
14. [A case of unresectable advanced pancreatic tail cancer successfully treated with gemcitabine hydrochloride].
Akutsu Y; Endo M; Yoshinaga Y; Hoshino T; Ota Y; Tsunoda Y; Matsubara H; Ochiai T
Gan To Kagaku Ryoho; 2005 Feb; 32(2):243-5. PubMed ID: 15751642
[TBL] [Abstract][Full Text] [Related]
15. A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma.
Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakagawa N; Takahashi S; Ohge H; Sueda T
Cancer Chemother Pharmacol; 2017 Apr; 79(4):775-781. PubMed ID: 28293715
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression.
Kobayashi M; Mizuno S; Murata Y; Kishiwada M; Usui M; Sakurai H; Tabata M; Ii N; Yamakado K; Inoue H; Shiraishi T; Yamada T; Isaji S
Pancreas; 2014 Apr; 43(3):350-60. PubMed ID: 24622063
[TBL] [Abstract][Full Text] [Related]
17. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma.
Rogers JE; Mizrahi JD; Xiao L; Mohindroo C; Shroff RT; Wolff R; Varadhachary GR; Javle MM; Overman M; Fogelman DR; Raghav KPS; Pant S; McAllister F
Cancer Med; 2020 Aug; 9(15):5406-5415. PubMed ID: 32519420
[TBL] [Abstract][Full Text] [Related]
18. Preoperative chemoradiotherapy using gemcitabine for pancreatic ductal adenocarcinoma in patients with impaired renal function.
Tomimaru Y; Eguchi H; Iwagami Y; Akita H; Noda T; Gotoh K; Kobayashi S; Nagano H; Mori M; Doki Y
Cancer Chemother Pharmacol; 2020 Mar; 85(3):537-545. PubMed ID: 31834436
[TBL] [Abstract][Full Text] [Related]
19. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
[TBL] [Abstract][Full Text] [Related]
20. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
Ma L; Fan Z; Du G; Wang H
Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
